HighTide Therapeutics, today announced that it has been invited to deliver two presentation at Phar-East 2019, to be held March 18–20 in Singapore.

Emerging Company Profile: Fatty liver disease has been a hot development area that keeps getting more attention, and one Chinese startup backed by the world’s largest heparin manufacturer is looking to launch a new therapy globally.

Jeffrey Dao, Operations & Business Development Officer to present HighTide’s HTD1801 for primary sclerosing cholangitis (PSC) at the World Orphan Drug Congress USA 2019 in Oxon Hill, MD...